Kailera Therapeutics Completes $625M IPO, One of Largest in Biotech History

Kailera Therapeutics completed a $625 million IPO, surpassing its initial target and becoming one of the largest biotech IPOs ever. The company, which focuses on obesity drugs, will begin trading on the Nasdaq under the ticker KLRA. The IPO highlights a growing trend of large fundraising in the biotech sector in 2026.

By Gwendolyn Wu Thu, April 16, 2026 at 11:38 PM GMT+3 3 min read · Yahoo Finance · April 16, 2026, 20:38 UTC

Tickers: $LLY $MRNA $NVO $SANA

Topics: Biotech Funding IPO Kailera Therapeutics Venture Capital

Read the full article at Yahoo Finance

More World news

Jensen Huang Resigns as Nvidia CEO Amid Personal Conduct Controversies and China Export Investigations Motley Fool · November 12, 2026, 18:56 UTC
The Adecco Group Reports Q3 2026 Growth Driven by Temporary Staffing and Margin Expansion PR Newswire · November 12, 2026, 18:54 UTC
Twist Bioscience Projects FY2027 Revenue Between $550M and $560M Seeking Alpha · November 12, 2026, 18:50 UTC
Dixie Group Reports Q3 Sales Growth Amid Margin Pressure and Future Cost-Reduction Targets Seeking Alpha · November 12, 2026, 18:50 UTC
Data I/O Corporation Targets Rapid V-TEK Synergy Realization Amid $80 Million M&A Pipeline Seeking Alpha · November 12, 2026, 18:50 UTC
Leatt Corporation Reports 43% Increase in Q3 Revenue to $20.46 Million Seeking Alpha · November 12, 2026, 18:50 UTC
Parsons Reports Strong Third Quarter Results Driven by High-Margin Product Shift Motley Fool · November 12, 2026, 18:45 UTC
C.H. Robinson Reports Q3 2026 Earnings Driven by AI Efficiency and Margin Expansion Motley Fool · November 12, 2026, 18:45 UTC
Baker Hughes Raises Guidance Amid Surging Data Center Power Demand Motley Fool · November 12, 2026, 18:45 UTC
California Supreme Court to Rule on Insurance Overcharge Liability Under Proposition 103 PR Newswire · November 12, 2026, 18:44 UTC